Bayer requests review periods exceeding 12 years to guarantee the supply of medicines. They argue substitution would require new clinical studies and complex regulatory re-validation. Bayer avoids high costs and regulatory hurdles by maintaining its current drug manufacturing processes.
Environmental interests lose as the phase-out of hazardous chemical emissions is significantly delayed.